Medivir AB: Clinical Phase I Trial With Hepatitis C Virus Protease Inhibitor Initiated

STOCKHOLM, Sweden--(BUSINESS WIRE)--Medivir, on behalf of the Tibotec and Medivir collaborative project, announced that this week Tibotec initiated a phase I clinical trial with a potent and selective hepatitis C virus (HCV) NS3/4A protease inhibitor, for the treatment of chronic hepatitis C virus infection. The phase Ia clinical trial is designed to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The study will be conducted in Europe.
MORE ON THIS TOPIC